Slide 1: Corporate Presentation June 2025
£ipca A dose of life Ipca Laborato Corporate Presentation June 2025
Slide 2: About Us
About Us a Q@00€ Incorporation “Consolidated income! Export to >16,000 | 70+ | FY202425 = JQO+ Employees . Maniecug bs years 39,032 cs | countries with sites labs ~ 0 ' USS1, 067 Mn onesie |
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _— Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards people | business practices
Slide 4: Five Years' Highlights
Five Years’ Highlights XN 6,749.21 %6,277.75 ($797.50) %5,925.81 ($757.82) ($738.69) %5,491.22 5,201.40 ($737.38) ($699.20) ace 3,570.05 ($465.59) 3,282.39 2,983.09 ($409.17) a) bier ($400.58) 333.94 oO -O- ~° %2,508.13 2,643.42 %2,707.70 2,808.96 ede ($336.80) (5329.52) ($326.86) ($331.91) —~CO- —O
Slide 5: Five Years' Highlights
Five Years’ Highlights Consolidated 9,032.39 10000 ($1,067.28) 9000 27,829.81 ($945.17) nee ——— %6,369.94 7000 | &5,432.83 aaah (5794.06) 6000 ($737.03) eagou.as 5000 vane ($578.30) 3,391.06 ($451.47) 2,818.61 i 4000 22,519.77 (5378.49) (5422.72) 4,138.23 4089.87 ($488.98) (5338.72) 3000 §-——0 2000
Slide 6: Manufacturing Sites: Formulations
Slide 7: Manufacturing Sites Formulations
B capital BD Corporate Office @ Formulations B Biotech Overseas ———_——se ¥ Pisgah Labs (North Carolina, USA) (Injectable & Oral Liquids) Kandla (B-lactum) Mumbai (Biotech) Baddi* Dehradun (2 facilities) (2 facilities) a Ghaziaba Athal t d? Mumbai + Goat Manufacturing Sites New Delhi Formulations Jor
Slide 8: Manufacturing Sites: Formulations
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry Syrups Tablets & Capsules Table
Slide 9: Manufacturing Sites: Active Pharmaceutical Ingredients
Manufacturing Sites < Active naceutical Ingredients hace : “
Slide 10: Manufacturing Sites: APIs
Manufacturing Sites APIs Onyx Scientific (Sunderland, UK) Baroda Dewas Nandesari New Delhi Ratlam Ranu | B capital (R80) 4 BD Corporate Office apis B® reo Overseas !on~doleenislonim ere ’ Hingni Mumbai Pithampur* Mumbai Chh. Sambhajinagar a ¥ (R&D) Mahad Y ¥ (2 Facilities) ¥ Pisgah Labs Ankleshwar —
Slide 11: Manufacturing Sites: APIs
Manufacturing Sites APIs [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDOM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore(Madhya Pradesh) nig B,WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gujart) = nia Japan Me
Slide 12: Revenue Break-up 2023-24 & 24-25
pelenii e ‘Break -up 2023-24 & 20 24-25
Slide 13: Revenue Break-up
Revenue Break-up Standalone 2024-25 Total Total Revenue Exports Domestic 2024-25 2024-25 2024-25 2024-25 e e e Formulations: APIs Formulations e e e APIs Formulations : Export Domestic : APIs @ Formulations @ APIs @ Domestic @ Exports @ Formulations @ APIs @ Formulations @® APIs
Slide 14: Revenue Break-up
Revenue Break-up Standalone 2024-25 2023-24 TCs | Domestic | Exports | Total | Domestic | Exports | Total Growth | @ Branded Formulations 3,450.21 581.89 4,032.10 3,097.16 526.70 3,623.86 po Saco 489 133669 1,341.58 - 1,248.62 1,248.62 Tender Formulations © Total Formulations 3,455.10 1,918.58 5,373
Slide 15: Financials FY 2023-24 & FY 2024-25
Slide 16: FY 2024-25 vs FY 2023-24
FY 2024-25 FY 2023-24 Zs US$ Mn || Zs US$ Mn | % Growth © Total Income 6,749.21 797 6,277.75 758 8% e EBIDT 1,513.33 179 1,189.54 144 @ EBIDT% 22.66% - 19.29% - fF @ PBT 1,281.31 151 955.52 115 @ PAT 650.76 77 530.41 64 16 # After forex gain of $11.70 Crsas against £21.84 Crs for previous year.
Slide 17: Financials Standalone: Profitability
Financials Standalone CO Profitability | FY 2024-25 FY 2023-24 PBIDT 19.29% PBIDT 22.66% @ PsioT GB Pst WB PAT @ PeioT WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials Standalone: Net Profit
Financials Standalone FY 2024-25 FY 2023-24 @ Net Profit 22.7% 4.9%
Slide 20: Standalone Q1 FY26
Standalone Q1 FY26 Q1FY25 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,771.92 207 1,581.25 — e EBIDT 416.04 49 348.44 e EBIDT% 23.82% - 22.25% @ PBT 356.75 42 287.89 e@ PBT% 20.42% - 18.39% @ PAT# 262.04 31 204.13 e@ PAT% 15.00% - 13.03% # After forex loss of €9.12 Crs as against forex ga
Slide 21: Financials Consolidated
Financials Consolidated FY 2024-25 FY 2023-24 ZCrs US$ Mn | f ZCrs US$ Mn @ Total Income 9,032.39 1,067 7,829.81 e EBIDT 1,693.13 200 1,288.21 e@ EBIDT% 18.94% - 16.72% @ PBT* 1,336.19 158 842.67 @ PBT% 14.95% - 10.94% @ PAT* 737.68 87 547.35 e@ PAT% 8.25% - 7.10% # After forex gain of $33.01 Crsas
Slide 22: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 23: Financials Consolidated: Net Profit
Financials Consolidated FY 2024-25 FY 2023-24 @ Net Profit 34.8% 9.2%
Slide 24: Financials Consolidated Q1
Financials Consolidated Q1FY 26 Q1FY 25 Crs US$ Mn Crs US$ Mn @ Total Income 2341.51 274 2,113.24 e EBIDT 424.58 50 387.49 e@ EBIDT% 18.39% = 18.52% @ PBT# 330.51 39 290.39 @ PBT% 14.31% > 13.88% @ PAT* 233.21 27 192.24 @ PAT% 10.10% > 9.19% # After forex loss of £8.16 Crs as against €5.23 Crs for p
Slide 25: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups 2024-25 Domestic 2023-24 © Cardiovasculars®& Anti-Diabetics © Cardiovasculars®& Anti-Diabetics © Anti-Malarials © Anti-Malarials © NeuroPsychiatry © NeuroPsychiatry © Dermatology © Dermatology © Neutraceuticals e 1% 1% H © Neutraceuticals e -
Slide 26: Branded Formulations: Domestic
Slide 27: Branded Formulations Domestic
Branded Formulations a Domestic . 22 Market leaders in Allndia Rank 1QVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16¢ (MAT Jun’25) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR / BA)-6863 top 300 brands (Zerodol-SP, Zerodol-P
Slide 28: Branded Formulations Domestic Sales
Branded Formulations %3,097.16 ($374 Mn) %2,760.71 2,508.27 ($344Mn) ($337 Mn) %3,455.10 ($408.26MIn) 2021-22 2022-23 2023-24 2024-25 ~ / Domestic —O- 202425 2021-22 2022-23 2023-24 Figures in Crores. Sales
Slide 29: Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS rail —® Strong brand building with focused promotion ‘—e In-licensing / out-licensing to build business in the promoted therapy Portfolio optimisation, strategies to i
Slide 30: International Business
Internat tional ANN S Business _ ww
Slide 31: International Business
International Business a Registrations in 61 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 42% sales & Marketing offices in are now exported to over From exports ‘a 12 countries 100 countries across the globe
Slide 32: International Business Sales
International Business (— > %2,808.96 3000 %2,508.13 %2,643.42 ee 2-808. $ ($337 Mn) (5330 Mn) 2500 2000 1500 1000 500 —O- wr425 | . 201-2 \ 2021-22 2022-23 2023-24 2024-25 ) 202273 Figures in Crores. Sales 32
Slide 33: Continent-wise Exports 2024-25
International Business a Continent-wise Exports 2024-25 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 525.00 281.11 806.11 29% © Africa 502.30 43.40 545.70 19% © Americas 267.43 268.57 536.00 19% © Asia 137.22 254.64 391.86 14% e ds 210.42 35.84 246.26 9% © Australasia 276.21
Slide 34: International Formulations
ee Interne a
Slide 35: International Formulations
International Formulations 21,918.58 21,775.32 ($227 Mn) %1,639.19 ($214Mn) ($204 Mn) 1,486.74 ($200 Mn) XX 2021-22 2022-23 2023-24 2024-25 ~ w —O— 2024-25 2021-22 2022-23 2023-24 Figures in Crores. Sales
Slide 36: International Branded Formulations
a International led Formulations =
Slide 37: International Branded Formulations
International Branded Formulations (— 581.89 >) 590 ($69 Mn) 570 550 526.70 530 504.79 ($64 Mn) an ($63 Mn) 490 470 450 %415.99 430 ($56 Mn) 410 390 370 350 —O- 2024-25 330 T T T 1 2021-22 L 2021-22 2022-23 2023-24 2024-25 O- 222 Figures in Crores. Sales 37
Slide 38: Future Growth Drivers
Future Growth Drivers ral International Branded Formulations Thrust on brand building in Pain, CVS, CNS, Anti-infective and Anti-malarial segments Geographical expansion in covered countries through additional field force Expansion in business lines - Institutions and Distributors Introduction of ne
Slide 39: International Generics
pert tional Ane SS SSS
Slide 40: International Generics / Institution / Tender
International Generics / Institution / Tender >) Products Products Under tog 1,248.62 ane | Country | Registered Registration | ($151 Mn) fen United Kingdom 1200 1,070.75 1,134.40 58 3 (5144 Mn) (3141 Mn) /Europe 1000 Australia / New Zealand tA 4 800 South Africa 53 10 600 United States / 50 5 400 C
Slide 41: Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries al Formulations registered to be backed by own API Sale of generic dossiers with or without supply agreements Contract manufacturing arrangements Future Gr
Slide 42: International APIs
peat tional
Slide 43: International APIs
International APIs ~ 200 1,021.39 1,004.23 ($137 Mn) ($125 Mn) ¥932,38 $890.38 1000 (5113 Mn) ($105 Mn) 800 600 400 200 —O- 202425 A 2021-22 2022-23 L 2021-22 2022-23 2023-24 2024-25 y 2023-24 Figures in Crores. Sales 4B
Slide 44: APIs - Drug Master Files
International APIs - Drug Master Files fl | DMF | Name of the API usrpa | Canada = wyo | 7aPa | pustralia | EQDM 1 1 Alendronate Sodium () c - v7) - Q@ 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () : - - - @ 4 Amlodipine Besylate (AK4 Process) - - - = ° g@ 4 5 Amodiaquine HCI = 2 @ - -
Slide 45: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 7 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlorth
Slide 46: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 20 23 21 24 22 25 23 26 24 27 28 25 29 30 26 31 27 32 28 33 Name of the API Citalopram HBR Dihydroartemesinin Donepezil Hydrochloride Monohydrate Duolexitine Hydrochloride Entacapone Etodolac (ED6 Process) Etodolac (ED7 Process) Famotidine Famotidine (FM3 Process) Fenofibr
Slide 47: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Jun’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- . Sr. No.| Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM | x0 35 Furosemide ° — 2 ° CEP Ad 36 Furosemide (Veterinary) 38 Felodipine ce 40 Hydrochlorothiazide (Process |
Slide 48: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Jun’25 (Based on DMFs Sr. No.) API | DMF Canada- Japan- . Sr. No.| Sr. No. Name of the API US-FDA HPFB WHO PMDA Australia EQDM | 46 Indapamide me 48 Losartan Potassium (LB4 Process) 49 Losartan Potassium (LB7 Process) 51 Meloxicam a 53 Me
Slide 49: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 55 45 56 46 57 47 58 59 48 60 49 61 62 50 63 51 64 52 65 Name of the API Metformin HCI (ML Process) Metformin HCI (ML2 Process) Methylphenidate HCI Metoclopramide Base Metoclopramide HCI Metoclopramide HCl (M Process) Metoprolol Succinate Metoprolol Tartrate Metoprolol Tar
Slide 50: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 53 66 54 67 55 68 56 69 57 70 58 71 59 72 60 73 61 74 62 75 63 76 Name of the API Olanzapine Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI Piperaquine Phosphate Primaquine Phosphate Proguanil Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyri
Slide 51: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 77 64 78 65 79 66 80 81 67 82 68 83 69 84 70 85 71 86 72 87 Name of the API Quetiapine Fumarate Quetiapine Fumarate (QT5 Process) Risendronate Sodium Hemi-Pentahydarate Risperidone Telmisartan Telmisartan (WT6 Process) Torsemide Tramadol Hydrochloride (YT3 Process) Trazodo
Slide 52: APIs - Drug Master Files
International APIs - Drug Master Files API-DMFs Filed as on Jun’25 (Based on DMFs Sr. No.) ‘sto | ome | Name of the API | US-FDA | Canada | WHO | Japan | Australia | EQDM | 73 88 __Venlafexine Hydrochloride go - - - - @ 748 Warfarin Sodium - - - - CEP 2 Warfarin Sodium Clathrate a
Slide 53: International APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe Future Growth Drivers ‘—© Long term strategic tie-ups with major South American / European formulators Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to introd
Slide 54: Research & Development: APIs & Formulations
Slide 55: Research & Development Spending
Research & Development APIs & Formulations ( ») Year | Xrs % to sales | 220 207-08 5.50% 200 : 5.00% 2020-21 126.67 2.49% 161.50 uy 14646 15649 2.64% Ges 2021-22 141.46 2.63% 160) = 2.63% 2.71% 4.00% ao | <126.67 3.50% 2022-23 156.49 2.71% 120 3.00% a An 2023-24 161.50 2.64% 80 2.00% 2024-25 207.08
Slide 56: Research & Development
Research & Development APIs & Formulations -—® Current scientist manpower of 640+ Research focus on developing APIs with non-infringing process and development of finished dosage forms Development of NDDS for domestic and international market 264 patent applications filed Biotech / fermentation rese
Slide 57: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable ofin-house development from “Clone to Commercialisation” Single-use CGMP Bio-manufacturing Facility (DS+DP+0C) is being established and to be ready by
Slide 58: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines Molecules: Anti-cancer, Anti-inflammatory and Opthalmic mAbs Stage of Development [ Molecules - Se © 7 Monoclonal antibodies (mAbs) and One Non- Pre-clinical | Clinical Trials | MAA /Launch mAb Biosimilar at various stages of the development UK/CA/IN/EU © Target markets I
Slide 59: Thank You